Autologous stem cell-based cancer immunotherapy - Medisun Precision Medicine/StemImmune

Drug Profile

Autologous stem cell-based cancer immunotherapy - Medisun Precision Medicine/StemImmune

Alternative Names: Autologous stem cell-mediated cancer therapeutic - Medisun Precision Medicine/StemImmune; Autologous stem cell-mediated immunotherapy - Medisun Precision Medicine/StemImmune

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator StemImmune
  • Class Antineoplastics; Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 17 Oct 2016 Accurexa and StemImmune agree to co-develop stem cell-mediated immunotherapy In USA for Cancer
  • 17 Oct 2016 Phase-I clinical trials in Cancer in USA (Parenteral) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top